Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) of Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with the Agency for Science, Technology and Research (A*STAR) Bioprocessing Technology Institute (BTI) and National University Health System (NUHS), have developed a groundbreaking technology capable of extracting mesenchymal stem cells (MSCs) directly from pure bone marrow – also known as bone marrow aspirate (BMA), a pivotal source of MSCs – without dilution.
Recent Posts
- Teenage daughter’s bone marrow saves dad’s life
- Woman shares leukemia battle, partial-match stem cell treatment with 1.5 million on social media
- CAR T-cell Therapy Improves Survival in Relapsed or Refractory Lymphoma
- New iron nanomaterial wipes out cancer cells without harming healthy tissue
- More Sensitive Cell Therapy May Be a HIT Against Solid Cancers

